DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story

starstarstarstarstar (1)
Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

Women's Health Homepage

Contrary to popular belief, deodorant OK for breast cancer patients: Study Radiation treatment outcomes are not impacted by antiperspirants

The advantages of using molecular breast imaging How to know if this secondary breast imaging modality is right for your facility

The future of breast density Tracy Accardi, vice president, global research and development, breast and skeletal health solutions at Hologic, on how artificial intelligence could be a game-changer for density interpretation

Experts see shift to tomo-only breast imaging Using tomo to produce synthetic 2-D mammo composite images

Breast Imaging Product Showcase Some of the best and newest innovations in breast imaging

Working moms are a driver of the U.S. economy Why being stingy with maternity leave is bad for business

Q&A with John Finlay, vice president of pathology solutions at Faxitron Discussing cabinet X-ray imaging technology and how specimen radiography is improving patient care

Purchasing Insights: Market trends in women’s health A look at the segments driving growth in breast imaging

Uterine Fibroids Treatment: Q&A with Dr. Suzanne LeBlang Highlighting the clinical advantages of using MR-guided focused ultrasound to treat uterine fibroids

Dense breast legislation and technological advances drive automated breast ultrasound Breast cancer screening gets personal

Molecular breast imaging finds cancers that mammograms don't: study

by Lisa Chamoff , Contributing Reporter
Molecular breast imaging (MBI) detected cancer in several women with dense breasts whose mammograms had been negative, with an incremental cancer detection rate of 7.7 per 1,000 screens, a study has found.

The retrospective study, published in the August issue of the American Journal of Roentgenology, examined data from the supplemental screening program at ProMedica Breast Care in Toledo, Ohio, from 2011 to 2014. After having a mammogram, 1,696 women with dense breast underwent supplementary screening with Gamma Medica’s LumaGEM MBI system, which uses the technetium-99m sestamibi radiopharmaceutical and employs a dual-head digital detector and a special collimator. This resulted in the detection of 13 malignancies, after the mammograms read negative for cancer.

Story Continues Below Advertisement

The (#1 Resource) for Medical Imaging and Peripherals. Call 1-949-273-8000

As a Master Distributor for major brands Barco, Philips, and Sony, we offer custom imaging solutions. With our renowned OEM Solutions and Service/Repair Center, Ampronix is a one-stop shop for HD Medical LCD Displays--Printers--Recorders--4K Cameras



“That’s a significant amount of extra cancers,” Dr. Robin Shermis, medical director at the ProMedica Breast Care Center and one of the study’s authors, told HCB News.

The lesion size ranged from .6 to 2.4 centimeters, with a mean of 1.1 centimeters. About 85 percent of the cancers were node negative, which means the prognosis was better.

“We found them early and they would have otherwise gone undetected by mammography,” Shermis said.

The study also found that the positive predictive value (PPV) for recall was 9.1 percent and the PPV for biopsy was 19.4 percent.

Shermis explained that patients at ProMedica Breast Care with a lifetime risk of at least 20 percent for developing breast cancer receive supplementary screening with MR, while patients with dense breast tissue are recommended to receive supplementary screening with MBI.

“MR is a great test, but it’s very expensive and insurance companies won’t pay for it unless you’re high risk,” Shermis said.

MBI delivers almost instantaneous results, he added.

“This new study in the AJR provides further evidence that women with dense breast tissue have more comfortable and less stressful alternatives to standardized secondary screening studies,” said Philip Croxford, chief executive officer of Gamma Medica, in a statement. “These recent clinical results suggest there is a real alternative to the risk of misdiagnosis and unnecessary biopsies.”

The study by ProMedica follows a study by the Mayo Clinic, published in the AJR last year, which found the addition of MBI to mammography increased the invasive breast cancer detection rate 363 percent, from 1.9 to 8.8 per 1,000 screens.

MBI uses 6 to 8 millicuries, about four times the dose from a digital mammogram, though Shermis said it’s possible to cut the dose in half by scanning for twice as long. While some breast cancer experts don’t recommend MBI for annual screening because of the higher dose, Shermis noted that it was important to weigh the risks with the benefit of detecting cancers earlier.

“Six thousand women, who know the benefits and risks, have yet to say ‘I don’t want it,’” Shermis said.

Women's Health Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED